Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants

Amanda M Hong1, Zahava Turner, Rana F Hamdy

  • 1The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Epilepsia
|May 19, 2010
PubMed

Insights

The ketogenic diet (KD) effectively treats intractable infantile spasms (IS) in about two-thirds of infants. Consider this diet after other treatments like corticosteroids and vigabatrin have failed.

Area of Science:

  • Neurology
  • Pediatrics
  • Dietary Therapy

Background:

  • Infantile spasms (IS) are a severe epilepsy syndrome in infants.
  • Intractable IS often requires exploring alternative treatment options.
  • The ketogenic diet (KD) has emerged as a potential therapy for refractory epilepsy.

Purpose of the Study:

  • To evaluate the efficacy and safety of the KD for infantile spasms (IS).
  • To assess the KD's impact on spasm frequency, development, and EEG findings.
  • To identify factors associated with positive treatment response.

Main Methods:

  • Prospective study of 104 infants with documented IS and hypsarrhythmia.
  • Infants were initiated on a traditional KD between 1996 and 2009.
  • Efficacy assessed via clinical evaluation, phone communication, and EEG monitoring.

Main Results:

  • 64% of infants showed >50% spasm improvement at 6 months; 37% became spasm-free.
  • 62% experienced developmental improvement, and 35% showed EEG improvement.
  • Adverse effects occurred in 33%, with diminished linear growth in 6%.

Conclusions:

  • The KD is an efficacious treatment for IS in approximately two-thirds of patients.
  • The KD should be strongly considered after failure of first-line therapies like corticosteroids and vigabatrin.
  • Older age at onset and fewer prior anticonvulsants predicted better spasm control.
Abstract

Related Concept Videos

Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...